A recent metanalysis in patients with MCI and AD showed that lithium significantly inhibited the progression of cognitive decline with moderate effect size and comparable side effects compared to placebo, though with no change in CSF biomarkers (Aβ1–42, total tau (t-tau) and hyperphosphorylated tau (p-tau)) [192]. Here, MAPT is linked to Alzheimer disease.